Anti‐MRSA Agent Discovery Using Diversity‐Oriented Synthesis
Gemma L. Thomas, Richard J. Spandl, Freija G. Glansdorp et al. · Angewandte Chemie International Edition · 2008
Beating the superbugs: Diversity-oriented synthesis using a solid-supported phosphonate unit to synthesize 242 drug-like compounds based on 18 natural-product-like scaffolds led to the discovery of gemmacin (see scheme). This new structural class of antibiotic is active towards methicillin-resistant Staphylococcus aureus (MRSA).
Cited by 134 works. doi:10.1002/anie.200705415
Authors
- Gemma L. Thomas
- Richard J. Spandl
- Freija G. Glansdorp
- Martin Welch
- Andreas Bender
- Joshua D. Cockfield
- Jodi A. Lindsay
- Clare Elizabeth Bryant
- Derek F. J. Brown
- Olivier Loiseleur
- Hélène Rudyk
- Mark Ladlow
- David R. Spring
References
- The first practical method for asymmetric epoxidation
- Target-Oriented and Diversity-Oriented Organic Synthesis in Drug Discovery
- A Planning Strategy for Diversity‐Oriented Synthesis
- Chiral Bis(oxazoline) Copper(II) Complexes: Versatile Catalysts for Enantioselective Cycloaddition, Aldol, Michael, and Carbonyl Ene Reactions
- Horner-wadsworth-emmons reaction: Use of lithium chloride and an amine for base-sensitive compounds
- LYSOSTAPHIN: A NEW BACTERIOLYTIC AGENT FOR THE STAPHYLOCOCCUS
- Platensimycin is a selective FabF inhibitor with potent antibiotic properties
- Antibiotics
- Antibiotics: Actions, Origins, Resistance
- Tandem Ring Opening−Ring Closing Metathesis of Cyclic Olefins